The impact of osteopontin on prognosis and clinicopathology of colorectal cancer patients: A systematic meta-analysis

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Zhao, Mingfei ^a   Liang, Feng ^a   Zhang, Buyi ^a   Yan, Wei ^a   Zhang, Jianmin ^a  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPONTIN; TUMOR MARKER;

COLORECTAL TUMOR; GENE EXPRESSION; GENETICS; HUMAN; META ANALYSIS; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; GENE EXPRESSION; HUMANS; OSTEOPONTIN; PROGNOSIS; SURVIVAL RATE;

EID: 84938370138     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep12713     Document Type: Article

References (28)

1. Siegel, R. L., Jemal, A., Thun, M. J., Hao, Y. & Ward, E. M. Trends in the incidence of colorectal cancer in relation to county-level poverty among blacks and whites. J Natl Med Assoc. 100, 1441-4 (2008).
2. Bandopadhyay, M. et al. Osteopontin as a therapeutic target for cancer. Expert Opin Ther Targets. 18, 883-95 (2014).
3. Ashkar, S. et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science. 287, 860-4 (2000).
4. Shin, T. Osteopontin as a two-sided mediator in acute neuroinflammation in rat models. Acta Histochem. 114, 749-54 (2012).
5. Zhang, J. et al. Differential osteopontin expression in lung cancer. Cancer Lett. 171, 215-22 (2001).
6. Bramwell, V. H. et al. Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial. Breast Cancer Res. 16, R8 (2014).
7. Kim, J. Y., Bae, B. N., Kim, K. S., Shin, E. & Park, K. Osteopontin, CD44, and NFkappaB expression in gastric adenocarcinoma. Cancer Res Treat. 41, 29-35 (2009).
8. Shang, S. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology. 55, 483-90 (2012).
9. Likui, W., Hong, W. & Shuwen, Z. Clinical significance of the upregulated osteopontin mRNA expression in human colorectal cancer. J Gastrointest Surg. 14, 74-81 (2010).
10. Zhao, M., Xu, H., Liang, F., He, J. & Zhang, J. Association of osteopontin expression with the prognosis of glioma patient: a meta-analysis. Tumour Biol. 36, 429-36 (2015).
11. Rohde, F. et al. Expression of osteopontin, a target gene of de-regulated Wnt signaling, predicts survival in colon cancer. Int J Cancer. 121, 1717-239 (2007).
12. Chen, S. H., Feng, Z. J., Jiang, W., Chen, F. & Sun, X. W. Expression of osteopontin and p21 inprimary colorectal cancer and their clinical significance. Modern Oncology. 115, 1132-1134 (2007).
13. Wang, X. F., Ni, Y. H., Wang, B., Zhang, M. & Guo, X. R. Expression and significance of osteopontin in colon cancer tissues. Jiang Su Med J. 34, 129-130 (2008).
14. Chen, Y. et al. Clinical significance of combined diagnostic tests of serum markers in detecting metastasis colorectal cancer. Clinical Medical Journal of China. 16, 94-96 (2009).
15. Wild, N. et al. A combination of serum markers for the early detection of colorectal cancer. Clin Cancer Res. 16, 6111-21 (2010).
16. Zhao, M., Yang, B., Huang, L. & F, X. Q. Expression of osteopontin and matrix metalloproteinase-9 in the colorectal cancer and its clinical significance. J Shanxi Med Univ. 42, 379-382 (2011).
17. Lin, A. Y. et al. Comparative profiling of primary colorectal carcinomas and liver metastases identifies LEF1 as a prognostic biomarker. PLoS One. 6, e16636; doi: 10.1371/journal.pone.0016636 (2011).
18. Yang, L. J. & Chen, Z. Correlation between the expression of OPN and MMP-9 in colorectal cancer and liver metastasis. Contemporary Medicine. 18, 7-9 (2012).
19. Li, J., Yang, G. Z., Zhu, Z. M., Zhou, Z. Y. & Li, L. Osteopontin is overexpressed in colorectal carcinoma and is correlated with P53 by immunohistochemistry. Exp Ther Med. 3, 621-624 (2012).
20. Sun, L. et al. Combination of haptoglobin and osteopontin could predict colorectal cancer hepatic metastasis. Ann Surg Oncol. 19, 2411-9 (2012).
21. Uhlmann, M. E., Georgieva, M., Sill, M., Linnemann, U. & Berger, M. R. et al. Prognostic value of tumor progression-related gene expression in colorectal cancer patients. J Cancer Res Clin Oncol. 138, 1631-40 (2012).
22. Rao, G. et al. Reciprocal interactions between tumor-associated macrophages and CD44-positive cancer cells via osteopontin/CD44 promote tumorigenicity in colorectal cancer. Clin Cancer Res. 19, 785-97 (2013).
23. Wang, C. J., Yang, G. G., Ding, J. & Liao, X. J. Expression and Clinical Significance of Gli1 and OPN in Colorectal Cancer. J Med Res. 43, 135-137 (2014).
24. Viana Lde, S. et al. Relationship between the expression of the extracellular matrix genes SPARC, SPP1, FN1, ITGA5 and ITGAV and clinicopathological parameters of tumor progression and colorectal cancer dissemination. Oncology. 84, 1-91 (2013).
25. Ratto, C. et al. Prognostic factors in colorectal cancer. Literature review for clinical application. Dis Colon Rectum. 41, 1033-49 (1998).
26. Lee, I. K. et al. Prognostic value of CEA and CA 19-9 tumor markers combined with cytology from peritoneal fluid in colorectal cancer. Ann Surg Oncol. 16, 861-70 (2009).
27. Cardella, J. et al. Compliance, attitudes and barriers to post-operative colorectal cancer follow-up. J Eval Clin Pract. 14, 407-15 (2008).
28. Nitsche, U. et al. Integrative marker analysis allows risk assessment for metastasis in stage II colon cancer. Ann Surg. 256, 763-71 (2012).